Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01560585 · ClinicalTrials.gov registry record · Phase 1
Open Label Study of Isotretinoin in Mild to Moderate Alzheimer's Disease
A Phase 1 study, sponsored by University Hospitals Cleveland Medical Center.
- Terminated
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT01560585 is a Phase 1 study that was terminated before completion, run by University Hospitals Cleveland Medical Center. The registered enrollment target is 3 participants.
The verdict
NCT01560585, a Phase 1 study, was terminated before completion, sponsored by University Hospitals Cleveland Medical Center.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
This is an open label study of isotretinoin, a medication which is FDA approved for treatment of other conditions to determine initial safety in Alzheimer's disease.
Interventions
- DRUG Isotretinoin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2012-04 |
| Est. Completion | 2014-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01560585
The ClinicalTrials.gov registry entry for NCT01560585 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University Hospitals Cleveland Medical Center, which has 230 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Isotretinoin is the first listed.
NCT01560585 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01560585 about?
NCT01560585 is a clinical study titled "Open Label Study of Isotretinoin in Mild to Moderate Alzheimer's Disease". This is an open label study of isotretinoin, a medication which is FDA approved for treatment of other conditions to determine initial safety in Alzheimer's disease.
What is the current status of trial NCT01560585?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2012-04. Estimated completion is 2014-08.
What interventions are being tested in trial NCT01560585?
The interventions under investigation include: Isotretinoin (DRUG).
Who is sponsoring clinical trial NCT01560585?
This trial is sponsored by University Hospitals Cleveland Medical Center, which has 230 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.